AbbVie calls off PhI trial for I-Mab’s CD47 days after Zai Lab shelves its own program
The CD47 field ran into another hurdle Tuesday as I-Mab quietly disclosed in an SEC filing that AbbVie is saying goodbye to a Phase I study of the biotech’s drug.
Weeks after ending an exploratory trial of I-Mab’s CD47 antibody, AbbVie has now called it quits on another early-stage trial. The Phase I was testing the drug, lemzoparlimab, in combination with azacitidine and venetoclax in patients with acute myeloid leukemia and myelodysplastic syndrome.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.